Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell ...

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...

ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...

and hold promise to further boost the median survival of patients with EGFR mutated NSCLC. Mutation; Lung cancer; Non-small-cell lung cancer; EGFR; EGFR inhibitor; Precision therapies; Resistance Pie ...

An ongoing clinical trial called "BREAKWATER" is showing great promise for metastatic colon cancer patients with a particular ...

New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...

An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...